Bristol Myers Squibb (BMY) Equity Income (2009 - 2024)

Bristol Myers Squibb (BMY) has reported Equity Income for 15 consecutive years, with -$23.0 million the latest figure, recorded in Q3 2024.

• On a quarterly basis, Equity Income fell 227.78% year-over-year to -$23.0 million in Q3 2024; TTM through Sep 2024 was $12.0 million, a 84.42% decrease from a year earlier, with the FY2019 full-year figure at -$4.0 million, down 104.3% from the prior year.
• Equity Income was -$23.0 million for Q3 2024 at Bristol Myers Squibb, down from $28.0 million in the prior quarter.
• Over five years, Equity Income peaked at $40.0 million in Q3 2021 and troughed at -$23.0 million in Q3 2024.
• A 4-year average of $13.7 million and a median of $23.0 million in 2023 frame the typical range for Equity Income.
• The widest YoY moves for Equity Income: up 354.55% in 2024, down 227.78% in 2024.
• Over 4 years, Equity Income stood at $30.0 million in 2020, then surged by 33.33% to $40.0 million in 2021, then sank by 55.0% to $18.0 million in 2023, then sank by 227.78% to -$23.0 million in 2024.
• The last three Equity Income figures came in at -$23.0 million (Q3 2024), $28.0 million (Q2 2024), and $18.0 million (Q3 2023), per Business Quant data.